LaChapelle Robin 4
4 · ArriVent BioPharma, Inc. · Filed Sep 23, 2024
Insider Transaction Report
Form 4
LaChapelle Robin
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2024-09-19$2.28/sh+2,471$5,634→ 112,219 total - Exercise/Conversion
Common Stock
2024-09-19$2.28/sh+2,867$6,537→ 102,584 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-19−2,471→ 2,460 totalExercise: $2.28Exp: 2031-09-07→ Common Stock (2,471 underlying) - Exercise/Conversion
Common Stock
2024-09-19$6.24/sh+2,700$16,848→ 99,717 total - Exercise/Conversion
Common Stock
2024-09-19$2.28/sh+7,164$16,334→ 109,748 total - Exercise/Conversion
Common Stock
2024-09-19$3.65/sh+12,364$45,129→ 124,583 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-19−2,867→ 22,637 totalExercise: $2.28Exp: 2032-01-31→ Common Stock (2,867 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-09-19−7,164→ 15,473 totalExercise: $2.28Exp: 2032-01-31→ Common Stock (7,164 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-09-19−12,364→ 18,865 totalExercise: $3.65Exp: 2033-01-31→ Common Stock (12,364 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-09-19−2,700→ 56,471 totalExercise: $6.24Exp: 2033-08-21→ Common Stock (2,700 underlying)
Holdings
- 394,477(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust.
- [F2]The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F3]The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F4]The shares underlying this option vested as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F5]The shares underlying this option vested as to 25% on August 22, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.